NEW YORK, June 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Globally, the osteoporosis market displayed a 3.5% compound annual growth rate (CAGR) between 2005–09, reaching $9.4 billion in 2009. However, the launch of generic alendronate in the majority of markets resulted in a temporary decline in sales during 2009. The market will stabilize during the next 5 years due to generic incursion and then resume growth from 2015 as new drugs are launched.
Reasons to Purchase
*Understand historical (2005–09) and future (2010–19) osteoporosis drug market dynamics and competitive environment.
*Gain insight into the main opportunities and threats specific to the osteoporosis market.
*Evaluate the sales forecasts of marketed, generic, and key pipeline drugs to 2019 in the US, Japan, France, Germany, Italy, Spain, and the UK.
To order this report:
Intl: +1 805-652-2626